Soligenix Reports Promising Extended Treatment Results for Rare Lymphoma Therapy

Biopharmaceutical company Soligenix has reported encouraging interim results from an ongoing open-label study evaluating extended treatment with HyBryte, a novel therapy for early-stage cutaneous T-cell lymphoma (CTCL). The investigator-initiated study demonstrates potential advancements in managing this rare and difficult-to-treat disease.

The research focuses on evaluating HyBryte's effectiveness when administered for up to 54 weeks, building upon previous Phase 3 FLASH study findings. Notably, the majority of patients exhibited a strong treatment response by week 18, which represents a significant improvement over existing therapies that typically require six to 12 months to show meaningful results.

CTCL remains an orphan disease with limited therapeutic options, making this research potentially transformative for patients. The extended treatment study provides critical insights into the long-term efficacy and safety of synthetic hypericin, the active component of HyBryte.

Soligenix CEO Christopher J. Schaber emphasized the importance of these findings, highlighting the urgent need for effective CTCL treatments. The company is simultaneously preparing for a confirmatory 80-patient Phase 3 FLASH 2 replication study, which could further validate the treatment's potential.

The ongoing research represents a significant step toward developing a more targeted and efficient therapy for patients struggling with this rare lymphoma. By demonstrating improved outcomes with longer treatment durations, Soligenix is addressing a critical gap in current medical approaches to CTCL.

As the study progresses, the potential for HyBryte to become a groundbreaking treatment continues to grow. The company plans to provide additional updates as more data becomes available, potentially paving the way for regulatory approvals and worldwide commercialization.